Revolution Medicines, Inc. (NasdaqGS: RVMD)
Health Care · Biotechnology · US
$211.38
-0.09% today · +492.6% 1Y
Revolution Medicines, Inc. (NasdaqGS: RVMD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $45.31B and employs 883 people.
Over the last twelve months the share price has gained 492.6%, trading between 35.42 and 216.72.
Tweenvest scores Revolution Medicines, Inc. across four factors: quality 29/100. Its strongest factor is quality.
RVMD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $45.31B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -8.92
- Dividend yield
- —
- Beta (5Y)
- 1.40
- 52-week high
- $216.72
- 52-week low
- $35.42
- Avg volume (3M)
- —
- Shares outstanding
- 214.34M
- Employees
- 883
- Next earnings
- —
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
- ISIN
- US76155X1000
- Founded
- 2014
- Listed since
- Feb 13, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.